EUVIMEDEUVIMED entdecken
Crossref

Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations

Yuchen Wang, Zheyuan Shen, Roufen Chen, Xinglong Chi, Wenjie Li, Donghang Xu, Yan Lu, Jianjun Ding, Xiaowu Dong, Xiaoli Zheng

Bioorganic Chemistry · 2024

DOI: 10.1016/j.bioorg.2024.107553 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Yuchen Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou 310015,…. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 1, Triple Negative Breast Neoplasms, Molecular Dynamics Simulation, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The overexpression of FGFR1 is thought to significantly contribute to the progression of triple-negative breast cancer (TNBC), impacting aspects such as tumorigenesis, growth, metastasis, and drug resistance. Consequently, the pursuit of effective inhibitors for FGFR1 is a key area of research interest. In response to this need, our study developed a hybrid virtual screening method. Utilizing KarmaDock, an innovative algorithm that blends deep learning with molecular docking, alongside Schrödinger's Residue Scanning. This strategy led us to identify compound 6, which demonstrated promising FGFR1 inhibitory activity, evidenced by an IC50 value of approximately 0.24 nM in the HTRF bioassay. Further evaluation revealed that this compound also inhibits the FGFR1 V561M variant with an IC50 value around 1.24 nM. Our subsequent investigations demonstrate that Compound 6 robustly suppresses the migration and invasion capacities of TNBC cell lines, through the downregulation of p-FGFR1 and modulation of EMT markers, highlighting its promise as a potent anti-metastatic therapeutic agent. Additionally, our use of molecular dynamics simulations provided a deeper understanding of the compound's specific binding interactions with FGFR1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Fibroblast Growth Factor, Type 1Triple Negative Breast NeoplasmsMolecular Dynamics SimulationAntineoplastic AgentsDrug Screening Assays, AntitumorDose-Response Relationship, DrugProtein Kinase InhibitorsCell ProliferationHumansStructure-Activity RelationshipMolecular StructureDrug DiscoveryCell MovementMolecular Docking SimulationCell Line, TumorDrug Evaluation, Preclinical

Stichwörter der Autor:innen

FGFR1Hybrid virtual screeningKarmaDockResidue scanningTNBC

Substanzen

Receptor, Fibroblast Growth Factor, Type 1FGFR1 protein, humanAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou 310015, China; Hangzhou Institute of Innovative Medicine, College of Pharmace…
  • Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.
  • Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou 310015, China.
  • Department of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • School of Food Science and Technology, Jiangnan University, Wuxi 214122, China.

Zitieren

APA

Wang, Y., Shen, Z., Chen, R., Chi, X., Li, W., Xu, D., Lu, Y., Ding, J., Dong, X., & Zheng, X. (2024). Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107553

Vancouver

Wang Y, Shen Z, Chen R, Chi X, Li W, Xu D, et al. Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107553

BibTeX
@article{Wang2024,
  author = {Wang, Yuchen and Shen, Zheyuan and Chen, Roufen and Chi, Xinglong and Li, Wenjie and Xu, Donghang and Lu, Yan and Ding, Jianjun and Dong, Xiaowu and Zheng, Xiaoli},
  title = {Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations},
  journal = {Bioorganic Chemistry},
  year = {2024},
  doi = {10.1016/j.bioorg.2024.107553}
}
Kostenlos starten →